Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China; Clinical Research Center for Breast Cancer, Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Changsha, Hunan, China; Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China; Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Changsha, Hunan, China.
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Changsha, Hunan, China; Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China; Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Changsha, Hunan, China; Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Biomol Biomed. 2023 Jul 3;23(4):680-688. doi: 10.17305/bb.2022.8564.
Models for predicting axillary lymph node metastasis (ALNM) in breast cancer patients are lacking. We aimed to develop an efficient model to accurately predict ALNM. Three hundred fifty-five breast cancer patients were recruited and randomly divided into the training and validation sets. Univariate and multivariate logistic regressions were applied to identify predictors of ALNM. We developed nomograms based on these variables to predict ALNM. The performance of the nomograms was tested using the receiver operating characteristic curve and calibration curve, and a decision curve analysis was performed to assess the clinical utility of the prediction models. The nomograms that included clinical N stage (cN), pathological grade (pathGrade), and hemoglobin accurately predicted ALNM in the training and validation sets (area under the curve [AUC] 0.80 and 0.80, respectively). We then explored the importance of the cN and pathGradesignatures used in the integrated model and developed new nomograms by removing the two variables. The results suggested that the combine-pathGrade nomogram also accurately predicted ALNM in the training and validation sets (AUC 0.78 and 0.78, respectively), but the combine-cN nomogram did not (AUC 0.64 and 0.60, in training and validation sets, respectively). We described a cN-based ALNM prediction model in breast cancer patients, presenting a novel efficient clinical decision nomogram for predicting ALNM.
在乳腺癌患者中,预测腋窝淋巴结转移(ALNM)的模型仍然缺乏。我们旨在开发一种能够准确预测 ALNM 的有效模型。招募了 355 名乳腺癌患者,并将其随机分为训练集和验证集。应用单因素和多因素逻辑回归来确定 ALNM 的预测因子。我们基于这些变量开发了列线图来预测 ALNM。使用接收者操作特征曲线和校准曲线来测试列线图的性能,并进行决策曲线分析以评估预测模型的临床实用性。包括临床 N 分期(cN)、病理分级(pathGrade)和血红蛋白在内的列线图在训练集和验证集中准确预测了 ALNM(曲线下面积 [AUC] 分别为 0.80 和 0.80)。然后,我们探讨了整合模型中 cN 和 pathGrade 特征的重要性,并通过去除两个变量开发了新的列线图。结果表明,联合-pathGrade 列线图在训练集和验证集中也能准确预测 ALNM(AUC 分别为 0.78 和 0.78),但联合-cN 列线图不能(在训练集和验证集中 AUC 分别为 0.64 和 0.60)。我们描述了一种基于 cN 的乳腺癌患者 ALNM 预测模型,提出了一种新的有效的临床决策列线图来预测 ALNM。